A monthly roundup of business and people news in the pharmaceutical industry.

Noah Nasser discusses one of the most critical components of working with RWD.

Michael Grosberg discusses the issues that need to be addressed to bring drug prices down for patients.

Derrick Gastineau discusses the importance of finding the right spaces to ensure patients see accurate information about medications.

Doctor Harshit Jain, Founder and Global CEO of Doceree, spoke with Pharmaceutical Executive about the role of AI in programmatic marketing, and the expectations of developments in communication between healthcare professionals and pharmaceutical brands.

Replicate Bioscience partners with Novo Nordisk to advance self-replicating RNA therapies for obesity and type 2 diabetes, enhancing innovative treatment options.

Amylyx Pharmaceuticals halts Amx0035's Orion program for PSP, shifting focus to Avexitide and other promising treatments for neurodegenerative diseases.

Lawyers for Monarez argue that only the president can fire her and that she has no plans to resign.

Derrick Gastineau discusses the importance of patients’ hearing stories from other patients.

The Boehringer Ingelheim leader discusses his leadership style and how it impacts his team’s strategy.

Noah Nasser discusses the importance of keeping data still.

Bayer's Gadoquatrane, a low-dose MRI contrast agent, aims to enhance imaging safety and efficacy for chronic disease patients, pending FDA approval.

FDA approves COVID-19 vaccines from Moderna, Pfizer-BioNTech, and Novavax targeting the LP.8.1 sublineage of SARS-CoV-2, with eligibility limited to adults aged 65 years and older and those with underlying medical conditions that place them with a high risk for severe disease.

ACOG reaffirms support for COVID-19 vaccines during pregnancy, challenging recent CDC recommendations and emphasizing maternal and fetal health.

Pfizer initiates layoffs at its Bothell site as part of a broader cost-cutting strategy, aiming to enhance R&D efficiency and automation.

The merger integrates EVERSANA’s commercialization services with Waltz Health’s AI-powered payer tools to address patient affordability, streamline drug access, and reduce costs for high-expense therapies such as GLP-1s.

Eli Lilly's oral GLP-1 receptor agonist Orforglipron showed significant weight loss, A1C reduction, and cardiometabolic improvements in the Phase III Attain-2 trial, paving the way for global regulatory submissions.

With insured patients less likely to benefit, who actually does benefit from D2C?

Putnam’s CEO discusses advancements in oncology and how companies are working to ensure patients have access to these new treatments.

The collaboration provides BioArctic with an upfront payment of $30 million and potential milestone and royalty payments as the companies explore a novel drug candidate for severe neurological disorders.

The acquisition adds Furoscix, an FDA-approved furosemide infusion therapy for chronic heart failure and kidney disease, while strengthening MannKind’s pipeline and commercial presence in cardiometabolic and orphan lung diseases.

Genentech broke ground on a $700 million manufacturing facility in Holly Springs, North Carolina its first on the U.S. East Coast supporting next-generation obesity treatments and metabolic medicines as part of Roche’s broader $50 billion U.S. investment in innovation, job creation, and advanced biomanufacturing.

Derrick Gastineau discusses how the focus on weight loss medications has shifted in recent years.

The CDC appointed Retsef Levi, a vocal critic of mRNA Covid-19 vaccines, to lead its Covid-19 immunization workgroup, a panel tasked with reviewing vaccine safety and effectiveness, despite controversy surrounding his past calls for vaccine withdrawal.

Shiladitya Sengupta, founder, Vyome Therapeutics, explains how the company’s strong ties in India’s biotech and healthcare sectors are helping to create innovative solutions for global markets.